Twitter LinkedIn
Return to Wellspring

Communicate

Nucleosides Analogs for Cardiovascular and Neurodegenerative Diseases

Details

Project TitleNucleosides Analogs for Cardiovascular and Neurodegenerative Diseases
Track CodeP0606
Websitehttp://musc.technologypublisher.com/technology/10162
Short Description

The inventors have developed a synthetic, L-adenosine analog (L-30-ADMdA) that mimics the natural nucleoside and binds competitively to adenosine receptors.

Abstract

Technology: The inventors have developed a synthetic, L-adenosine analog (L-30-ADMdA) that mimics the natural nucleoside and binds competitively to adenosine receptors. The specificity of this analog for a range of adenosine receptors makes it uniquely suited for the study and potential treatment of cardiovascular and neurodegenerative diseases. When compared to a natural nucleoside in an ischemia/reperfusion model on Langendorff perfused mouse heart. L-30-ADMdA was found to enhance functional recovery from ischemia (32.2 ± 3.7 cm H2O/s % rate pressure product, compared to 21.3 ± 1.4 for the control and 30.7 ± 3.4 for adenosine) and increase the time to onset of ischemic contracture (14.5 ± 0.9 min, compared to 10.5 ± 1.0 min for the control and 13.6 ± 0.6 min for adenosine) comparable to adenosine.

 

Overview: Nucleoside analogs in both the D- and L- forms have been used therapeutically for a range of viral diseases including HIV, Hepatitis B, Herpes simplex and Hepatitis C; however, nucleosides are also involved in mediating non-viral cell processes. In particular, adenosine has been shown to interact with at least four specific receptors, which play different roles in a range of cardiovascular and neurological disorders. With proven low cell toxicity and high metabolic stability, the L-adenosine analog has strong potential both to aid further understanding of these receptors and for pharmacological development.

 

Advantages: Better nucleoside analog therapeutics for cardiovascular and neurodegenerative diseases

 

Key Words: Nucleoside analog, cardiovascular, neurodegenerative, adenosine

 

Publication: Kasiganesan, Harinath, et al. "Novel l-adenosine analogs as cardioprotective agents.Bioorganic & medicinal chemistry 17.14 (2009): 5347-5352.

 

Inventors:                               G. Gumina, C. Beeson, G. Wright

Patent Status:                        US Patent 7,423,025

MUSC-FRD Technology ID:    P0606

 
TagsNucleoside analog, cardiovascular, neurodegenerative, adenosine
 
Posted DateSep 28, 2016 12:24 PM

Offerings

Name Price
U.S. Issued Patent for Sale 20,000.00 USD Buy